ACTA1 Antibody

What is the expression profile of ACTA1 across different tissue types?

ACTA1 demonstrates highly specific expression patterns, primarily in skeletal muscle tissue. According to literature citations and experimental validation, ACTA1 is strongly expressed in skeletal muscle (PubMed IDs: 6190133, 15489334) . The protein localizes predominantly in the cytoplasm and cytoskeleton of muscle cells. Interestingly, ACTA1 expression has been confirmed in biceps brachii through immunohistochemical analysis, showing positive staining in the cytoskeletal elements of this muscle group . The expression pattern is consistent across human, mouse, and rat tissues, making it an excellent marker for comparative studies across these species.

How can researchers distinguish between different actin isoforms when using ACTA1 antibodies?

Distinguishing between actin isoforms presents a significant challenge due to their high sequence homology. When selecting an ACTA1 antibody, researchers should carefully examine the immunogen sequence. For example, the RP1070 antibody's immunogen is a synthetic peptide corresponding to the C-terminus of human Actin (359-377aa ITKQEYDEAGPSIVHRKCF), which is identical to the related mouse and rat sequences . To ensure specificity for ACTA1 over other actin isoforms, researchers should:

• Review the exact epitope sequence targeted by the antibody

• Conduct epitope alignment analyses against different actin isoforms

• Perform validation experiments using positive and negative control tissues

• Consider using blocking peptides to confirm specificity

• Implement western blot analysis to verify single-band specificity at the expected molecular weight of 42 kDa

What validation methods are essential before using an ACTA1 antibody in a new research context?

Thorough validation is critical before applying an ACTA1 antibody to new research questions. Based on established methodologies, researchers should:

Evidence from validation studies demonstrates that proper antibody validation should include multiple tissue types. For example, the RP1070 antibody was validated across multiple human cell lines (placenta tissue, Hela, HepG2, 293T, A431, U87, U937, K562) and various mouse and rat tissues (heart, brain, kidney, spleen) .

How should experimental conditions be optimized for ACTA1 antibody use in Western blot analyses?

Optimizing Western blot conditions for ACTA1 detection requires careful consideration of multiple parameters. Based on validated protocols, researchers should implement the following approach:

• Gel Selection: Use 5-20% SDS-PAGE gels for optimal separation

• Running Conditions: Apply 70V for stacking gel and 90V for resolving gel, for 2-3 hours

• Protein Loading: Load approximately 30 μg of sample per lane under reducing conditions

• Transfer Parameters: Transfer to nitrocellulose membrane at 150 mA for 50-90 minutes

• Blocking: Block with 5% non-fat milk in TBS for 1.5 hours at room temperature

• Primary Antibody Incubation: Use anti-ACTA1 antibody at 0.5 μg/mL concentration overnight at 4°C

• Washing: Wash with TBS-0.1% Tween three times, 5 minutes each

• Secondary Antibody: Probe with goat anti-rabbit IgG-HRP at 1:5000 dilution for 1.5 hours at room temperature

• Detection System: Develop using enhanced chemiluminescent detection systems

This protocol has been validated to detect a specific band for Actin at approximately 42 kDa, which aligns with the expected molecular weight.

What are the critical parameters for successful immunohistochemical detection of ACTA1 in tissue sections?

Successful immunohistochemical detection of ACTA1 requires attention to several critical parameters:

• Sample Preparation: Use paraffin-embedded tissue sections with appropriate fixation

• Antigen Retrieval: Perform heat-mediated antigen retrieval in EDTA buffer (pH 8.0)

• Blocking: Block non-specific binding with 10% goat serum

• Primary Antibody: Incubate with ACTA1 antibody at 2 μg/ml concentration overnight at 4°C

• Secondary Antibody: Use Peroxidase Conjugated Goat Anti-rabbit IgG, incubated for 30 minutes at 37°C

• Detection System: Develop using HRP Conjugated detection system with DAB as the chromogen

This protocol has been successfully applied to human breast cancer tissue, human colorectal adenocarcinoma tissue, mouse heart tissue, and rat heart tissue, demonstrating consistent and specific ACTA1 detection across different tissue types and species.

How can ACTA1 antibodies be utilized in studying skeletal muscle diseases and developmental disorders?

ACTA1 antibodies serve as powerful tools for investigating skeletal muscle pathologies and developmental abnormalities. Researchers can employ these antibodies to:

• Quantify ACTA1 expression changes in diseased versus healthy tissue

• Analyze structural alterations in the actin cytoskeleton

• Examine protein-protein interactions between ACTA1 and other muscle proteins

• Detect post-translational modifications affecting ACTA1 function

• Monitor developmental expression patterns during myogenesis

For skeletal muscle diseases, immunohistochemical analysis using ACTA1 antibodies can reveal characteristic changes in protein localization, expression levels, or aggregation patterns. The specific staining observed in biceps brachii cytoskeleton indicates the utility of these antibodies in examining structural integrity of muscle fibers .

What methodological approaches are recommended for studying ACTA1 in mesenchyme migration research?

For mesenchyme migration studies, ACTA1 antibodies provide valuable insights into cytoskeletal dynamics. Based on research methodologies, the following approaches are recommended:

• Live Cell Imaging: Combine fluorescently tagged ACTA1 antibodies with time-lapse microscopy

• Tissue Lysate Analysis: Validate antibody specificity on relevant tissue lysates before migration experiments

• Co-localization Studies: Pair ACTA1 antibodies with markers for focal adhesions or other migration-related structures

• Quantitative Analysis: Implement digital image analysis to quantify changes in actin cytoskeleton during migration

• Perturbation Experiments: Use ACTA1 antibodies to monitor cytoskeletal responses to migration-altering treatments

The RP1070 antibody has been validated on various tissue lysates including rat liver, kidney, mouse spleen, and multiple cell lines, making it suitable for mesenchyme migration research applications that require reliable detection of actin in diverse sample types .

What factors determine the cross-reactivity of ACTA1 antibodies across different species?

The cross-reactivity of ACTA1 antibodies across species depends on several key factors:

• Epitope Conservation: The degree of sequence homology at the antibody binding site

• Immunogen Design: Whether the antibody was raised against a conserved region

• Post-translational Modifications: Differences in protein processing between species

• Tissue-specific Expression Patterns: Variations in ACTA1 expression across species

For example, the RP1070 antibody's immunogen (a synthetic peptide corresponding to the C-terminus of human Actin, 359-377aa) is identical to mouse and rat sequences, explaining its validated cross-reactivity with these species . For untested species like canine or primate, researchers are advised to perform sequence homology analysis (BLAST) between the target species and the immunogen sequence to predict potential cross-reactivity .

How should researchers approach validation of ACTA1 antibodies in species beyond those already confirmed?

When extending the use of ACTA1 antibodies to new species, a systematic validation approach is essential:

• Sequence Analysis: Perform BLAST analysis between the immunogen sequence and the target species ACTA1 sequence

• Pilot Testing: Conduct preliminary experiments with positive controls from the new species

• Multiple Detection Methods: Validate using both Western blot and immunohistochemistry

• Tissue Panel Testing: Test across multiple tissues known to express ACTA1 at different levels

• Specificity Controls: Include blocking peptide controls and tissues known to lack ACTA1 expression

For example, when considering the use of RP1070 on canine tissues, although specific validation has not been performed, there is a reasonable probability of cross-reactivity based on sequence conservation . Similarly, for primate samples, while not directly validated, sequence homology analysis can provide guidance on potential cross-reactivity .

How can researchers address unexpected staining patterns when using ACTA1 antibodies?

When encountering unexpected staining patterns with ACTA1 antibodies, researchers should implement a systematic troubleshooting approach:

• Tissue Expression Verification: Confirm ACTA1 expression in the tissue of interest through literature or database searches

• Protocol Optimization: Adjust antibody concentration, incubation time, and antigen retrieval methods

• Specificity Testing: Perform blocking peptide competition assays to confirm binding specificity

• Positive Control Inclusion: Include known ACTA1-expressing tissues as positive controls

• Alternative Detection Methods: Confirm results using a different detection technique

For instance, when researchers observed positive staining in biceps brachii using the RP1070 antibody, reference to literature confirmed that ACTA1 is indeed expressed in this tissue, validating the observed pattern . According to Uniprot.org data and published literature, ACTA1 expression has been confirmed in biceps brachii and skeletal muscle through multiple studies (PubMed IDs: 6190133, 15489334) .

What methodological strategies can resolve inconsistent Western blot results with ACTA1 antibodies?

Inconsistent Western blot results with ACTA1 antibodies can be addressed through several methodological strategies:

The validated protocol using 5-20% SDS-PAGE gels, specific transfer parameters (150 mA for 50-90 minutes), and optimized antibody concentrations (0.5 μg/mL) has demonstrated consistent detection of the expected 42 kDa ACTA1 band across multiple samples .

What modifications to standard protocols are required when using ACTA1 antibodies in protein modification studies?

When studying post-translational modifications or structural variants of ACTA1, researchers should consider these protocol modifications:

• Gel Selection: Higher resolution gels (10-15%) may be needed to separate closely migrating modified forms

• Sample Preparation: Phosphatase or deubiquitinase inhibitors may be required to preserve modifications

• Control Samples: Include samples treated with modification-inducing or inhibiting agents

• Detection Systems: More sensitive detection systems may be necessary for low-abundance modified forms

• Antibody Selection: Consider using modification-specific ACTA1 antibodies when available

For specialized applications, researchers might need BSA-free antibody formulations, which can be specially prepared as indicated in the RP1070 product information .

How can researchers effectively distinguish between ACTA1 and other actin isoforms in co-expression studies?

Distinguishing between actin isoforms presents a significant challenge. To effectively differentiate ACTA1 from other actins in co-expression studies:

• Epitope Selection: Choose antibodies raised against isoform-specific regions

• Sequential Immunodetection: Use different detection methods for each isoform

• Knockout/Knockdown Controls: Include samples with selective depletion of specific isoforms

• Co-localization Analysis: Combine with known isoform-specific marker proteins

• Expression Pattern Analysis: Compare with known tissue-specific expression profiles

The immunogen sequence of RP1070 (359-377aa ITKQEYDEAGPSIVHRKCF) should be carefully compared to other actin isoforms to understand potential cross-reactivity . When researchers inquire about isotype reactivity, careful analysis of the immunogen sequence against specific isotypes is recommended to predict specificity .